Actover Pharmaceutical Group Showcases Its Neurology Portfolio at the 32nd Iranian Congress of Neurology and Clinical Electrophysiology
Tehran, May 2025 — Actover Pharmaceutical Group participated in the 32nd Iranian Congress of Neurology and Clinical Electrophysiology, presenting a wide range of its neurological products to healthcare professionals and field experts.
Actover Pharmaceutical Group Showcases Its Neurology Portfolio at the 32nd Iranian Congress of Neurology and Clinical Electrophysiology
Tehran, May 2025 — Actover Pharmaceutical Group participated in the 32nd Iranian Congress of Neurology and Clinical Electrophysiology, presenting a wide range of its neurological products to healthcare professionals and field experts.
According to Actover’s Public Relations Department, the congress was held from April 28 to May 1, 2025, at the Razi International Conference Center in Tehran, under the theme “Advances in Neurology, Inspiring Hope.” The event featured over 100 scientific papers presented in both oral and poster formats, covering key topics including multiple sclerosis, dementia, cerebrovascular disorders, neuromuscular diseases, movement disorders, headaches, general neurology, sleep disorders, rehabilitation, and the intersection of neurology and art.
Dr. Mahmoud Moatamedi, President of the Iranian Society of Neurologists, described the event as the most prestigious scientific gathering in the country for neurology and electrophysiology. He emphasized its role in fostering knowledge exchange and showcasing the latest advancements in research and treatment. The congress also featured specialized workshops, exhibitions, and a tribute honoring Professor Belal Adibek for his lifelong contributions to neurology in Iran.
As part of the accompanying exhibition, Actover Pharmaceutical Group presented its extensive neurology portfolio. With more than 50 years of history and a commitment to cutting-edge pharmaceutical manufacturing, Actover currently offers over 300 products across 15 therapeutic areas. Neurological treatments represent a significant share of its portfolio.
Highlighted products at the exhibition included:
- Anticonvulsants: Lacsa (Lacosamide), Valpact (Valproate), Eleppra (Levetiracetam)
- Multiple Sclerosis Treatments: Actovex, Gylenid (Fingolimod), Actiramer (Glatiramer Acetate), Tecra (Dimethyl Fumarate), Rituxiver (Rituximab)
- Neurology and Psychiatry Medications: Asentra (Sertraline), Tazadep (Mirtazapine), Quentiax (Quetiapine), Escitover (Escitalopram), Arizover (Aripiprazole), Yasnal (Donepezil), and Alventa (Venlafaxine)
